Tiffany (NYSE:TIF): Oppenheimer believes Tiffany’s is poised to resume growth, following a meeting with the company’s chief operating officer. The firm believes that signs of improving jewelry demand along with easing commodity costs position the company well for a return to positive earnings growth. It keeps an Outperform rating on the shares.
Navidea Biopharmaceutical (NYSEMKT:NAVB): Navidea’s financing deal with GE Capital removes a significant overhang, as do changes to its existing credit line and warrants, according to Ladenburg, which also believes that it is unlikely that the company will need additional equity capital to fund the commercial launch of Lymphoseek. Ladenburg maintains its Buy rating on the stock.
Workday (NYSE:WDAY): William Blair has assumed coverage of Workday, with an Outperform rating on the shares. The firm says Oracle’s partnership with Salesforce.com is unlikely to change the competitive landscape between Workday and Oracle.
Darden (NYSE:DRI): Oppenheimer sees Darden as being poised to outperform, and could beat expectations going forward with just an average level of execution. The firm thinks that the stock is an “intriguing” investment, in light of negative sentiment towards the name. It keeps an Outperform rating on the stock.
Don’t Miss: Can Men’s Wearhouse Continue This Bullish Run.